Eli Lilly Foundayo, the pharmaceutical giant’s newly launched oral weight-loss drug, stumbled out of the gate in its first week on the market, trailing well behind rival Novo Nordisk’s Wegovy pill. And yet, despite the underwhelming prescription numbers, Eli Lilly’s stock actually rallied on the news. What exactly is going on here, and why are investors still feeling optimistic about the drug’s future?
The answer lies in the details beneath the headline numbers, and it offers a fascinating look at how the oral weight-loss drug market is shaping up into one of the biggest pharmaceutical battles of the decade.
The Numbers at First Glance
According to analyst reports released Friday, Eli Lilly Foundayo recorded 1,390 prescriptions during its debut week on the market. That might sound like a respectable start, but the comparison to Novo Nordisk’s Wegovy pill tells a different story. The Wegovy oral version notched 3,071 prescriptions in its own first week, meaning Foundayo came in at less than half of its rival’s opening pace.
For a company that has been riding high on the success of its injectable weight-loss medications, this kind of gap in an oral drug launch might seem alarming on the surface. Oral formulations are widely expected to expand the weight-loss drug market significantly, and being first with a strong product matters enormously.
So why did Lilly’s stock jump 2.6 percent to close at $927.03 while Novo’s shares fell 1 percent to $40.52? The market is clearly seeing something that the raw prescription numbers alone do not capture.
The Time Factor Changes Everything
RBC Capital Markets analyst Trung Huynh pointed out a critical nuance in a recent research note. Wegovy’s first week of sales covered five full days on the market. Foundayo, on the other hand, likely had just two days available for prescriptions in its opening week.
When you adjust for that timing difference, the picture shifts dramatically. On a per-day basis, Foundayo’s launch actually looks quite robust, suggesting the drug built meaningful momentum over the three additional days of the week that were not captured in the initial reporting window.
This reframing is why Lilly shares not only climbed but also closed back above their 200-day moving average, a key technical level that many investors use to gauge longer-term stock health. The market essentially agreed with the analyst view that Foundayo’s launch is stronger than the top-line number implies.
What Investors Should Watch Next
While the early enthusiasm is encouraging, analysts caution that the story is just getting started. Huynh expects prescription numbers to show some volatility in the coming weeks as the launch normalizes. That kind of turbulence is typical for major drug debuts and should not necessarily be cause for concern.
The real test, according to Huynh, will come during weeks eight through twelve. That is when the market typically gets a clearer read on whether a new drug is building sustainable demand. Key factors to watch during that period include:
- Stable week-over-week growth in prescriptions
- Solid refill rates from existing patients
- Strong prescriber preference among doctors
- Patient satisfaction and continued use
By week twelve, which lands around mid-June, Huynh estimates Foundayo would need to reach over 90,000 weekly prescriptions to stay on track for consensus revenue projections of roughly $1.4 billion. Interestingly, analysts expect Wegovy’s oral version to hit a similar number this year, suggesting the two drugs could end up in a tight, head-to-head competition.
The Refill Rate Question
Evercore ISI analyst Umer Raffat is focused on a different but equally important metric: refill rates. This might sound like a minor detail, but it could end up being one of the most critical factors in determining which drug wins the long-term battle.
A month ago, Raffat estimated that somewhere between 20 and 30 percent of oral Wegovy patients were not transitioning to the next dose level on the schedule their doctors recommended. That is a potential red flag, and the reason behind it matters for understanding how Foundayo might perform.
Understanding the Titration Process
GLP-1 drugs, which are the class of medications that both Foundayo and Wegovy belong to, need to be titrated carefully. Titration simply means gradually increasing the dose over time so the body can adjust. This slow ramp-up is essential because these drugs can cause unpleasant gastrointestinal side effects, including nausea and vomiting, if patients try to start at full strength.
For the Wegovy pill, the titration schedule moves patients from a 4-milligram dose up to 9 milligrams and eventually to 25 milligrams. However, the data shows there are about 50 percent fewer prescriptions for the 9-milligram Wegovy pill than would be expected based on the January launch date and standard titration schedule.
Several factors could be driving this gap:
- A $100 price increase when patients move from 4 milligrams to 9 milligrams
- Patients choosing to skip doses to save money
- Patients skipping doses to manage side effects on their own terms
- Physicians delaying titration due to patient tolerance issues
Why This Matters More for Foundayo Than Wegovy
Here is where things get particularly interesting for Eli Lilly. Wegovy is a peptide-based drug that stays in the body for about five days. That long half-life means that if a patient occasionally misses a dose, their drug levels remain relatively stable and side effects usually do not flare up significantly.
Foundayo works very differently. The drug stays in the body for less than 24 hours, which means skipping doses could have a much more immediate and uncomfortable impact. Patients who miss doses might experience spikes in nausea and vomiting when they resume their medication, making compliance potentially more challenging.
This difference in pharmacokinetics could end up being a real hurdle for Foundayo if patients treat it the way many are apparently treating Wegovy. The drug’s success will depend not just on doctors prescribing it, but on patients taking it consistently and moving through the titration schedule as intended.
Raffat noted that this broader theme around refills and compliance will be a major factor to watch as Foundayo’s launch unfolds over the coming months.
The Bigger Picture for Oral Weight-Loss Drugs
Zooming out, the battle between Eli Lilly Foundayo and Novo Nordisk’s oral Wegovy represents the next major frontier in the weight-loss drug market. Injectable GLP-1 medications have already transformed obesity treatment, but injections come with barriers. Many patients dislike needles, injections require more training and storage considerations, and compliance can suffer over time.
Oral versions of these drugs have the potential to dramatically expand the market by reaching patients who would never consider an injection. Some industry estimates suggest oral GLP-1 drugs could open up a patient population several times larger than the current injectable market.
For Eli Lilly, winning meaningful share in the oral category is critical to maintaining its dominance in the broader weight-loss space. The company’s injectable drug Zepbound has been a blockbuster, but standing still is not an option in a market where Novo Nordisk continues to push aggressively.
Why Lilly Investors Are Staying Patient
The modest rally in Eli Lilly stock despite the lower prescription numbers sends a clear message. Investors are looking past the first-week headline and focusing on the trajectory. They believe Foundayo has the clinical profile, the marketing muscle behind it, and the brand reputation to eventually carve out significant market share.
There is also the reality that launching a drug in a market where a competitor already has a head start is inherently challenging. Patients who are already on Wegovy are unlikely to switch immediately. New prescriptions are where Foundayo will make its mark, and those take time to build up as doctors become comfortable with the drug and its side effect profile becomes better understood in real-world use.
What Happens Over the Next Three Months
The coming weeks will offer a much clearer picture of how Foundayo is performing. Watch for signs of steady week-over-week growth, solid refill rates, and evidence that doctors are comfortable moving patients through the titration schedule without dropping off.
If Foundayo can demonstrate those qualities, the $1.4 billion revenue target becomes much more achievable, and Eli Lilly will have successfully established itself as a major player in the oral weight-loss market. If the drug struggles with compliance or refill issues similar to what Wegovy is experiencing, the stock may face more headwinds.
For now, the early signs suggest cautious optimism is warranted. The launch may not have matched the opening-week fireworks of Novo’s Wegovy pill, but the underlying momentum looks solid when viewed through the right lens. And in pharmaceuticals, as in most long-term businesses, the race is rarely won in the first week.
Eli Lilly Foundayo has a long road ahead, but for investors willing to look past the surface numbers, the journey looks promising so far.
